The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences’ HIV drug Biktarvy and Pfizer’s arthritis treatment Xeljanz.
It is the third round of drugs subject to former President Joe Biden’s Inflation Reduction Act of 2022, which allowed the government to negotiate prices of some drugs purchased by the U.S. Medicare health program for people aged 65 and older or with disabilities.
Despite the industry’s longstanding opposition to the law and multiple failed lawsuits, the first negotiated prices on 10 drugs sold in pharmacies went into effect this year.
The 2028 list also includes products that are administered in doctors’ offices or hospitals, such as Novartis psoriasis drug Cosentyx and Botox, which is made by AbbVie.
Other medications up for negotiation include Eli Lilly’s GLP-1 diabetes drug Trulicity.
